Loading...
If your product does not perform as described on this datasheet, we will refund or replace your product...
Read our guarantee »Products:Epigenetics and Nuclear Signaling >> Transcription >> Polymerase associated factors >> Pol II Transcription
Anti-RNA polymerase II CTD repeat YSPTSPS antibody
See all RNA polymerase II CTD repeat YSPTSPS products (17) ...
Rabbit polyclonal to RNA polymerase II CTD repeat YSPTSPS
ab52202 detects endogenous levels of total RNA polymerase II protein.
WB, IHC-P, ELISAmore details
Reacts with
Mouse, Rat, Human
Synthetic non-phosphopeptide derived from human RNA polymerase II CTD repeat YSPTSPS around the phosphorylation site of serine 5 (P-T-S-P-S).
WB: extracts from COS7 cells treated with EGF (200ng/ml, 30min). IHC-P: human breast carcinoma tissue.
Liquid
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Preservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, PBS, 150mM Sodium chloride, pH 7.4
Concentration information loading...
Immunogen affinity purified
Polyclonal
IgG
Epigenetics and Nuclear Signaling >> Transcription >> RNA polymerase
Epigenetics and Nuclear Signaling >> Transcription >> Polymerase associated factors >> Pol II Transcription >> Polymerase
Epigenetics and Nuclear Signaling >> Transcription >> Polymerase associated factors >> Pol II Transcription
Our Abpromise guarantee covers the use of ab52202 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: 1/500 - 1/1000.Detects a band of approximately 217 kDa (predicted molecular weight: 217 kDa).
IHC-P: 1/50 - 1/100.
ELISA: 1/10000
DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Forms the polymerase active center together with the second largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB1 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template. At the start of transcription, a single stranded DNA template strand of the promoter is positioned within the central active site cleft of Pol II. A bridging helix emanates from RPB1 and crosses the cleft near the catalytic site and is thought to promote translocation of Pol II by acting as a ratchet that moves the RNA-DNA hybrid through the active site by switching from straight to bent conformations at each step of nucleotide addition. During transcription elongation, Pol II moves on the template as the transcript elongates. Elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of Pol II largest subunit (RPB1), which serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. Acts as a RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicate and transcriptase for the viral RNA circular genome.
Belongs to the RNA polymerase beta' chain family.
The tandem 7 residues repeats in the C-terminal domain (CTD) can be highly phosphorylated. The phosphorylation activates Pol II. Phosphorylation occurs mainly at residues 'Ser-2' and 'Ser-5' of the heptapeptide repeat. The phosphorylation state is believed to result from the balanced action of site-specific CTD kinases and phosphataes, and a "CTD code" that specifies the position of Pol II within the transcription cycle has been proposed.
Dephosphorylated by the protein phosphatase CTDSP1.
Ubiquitinated by WWP2 leading to proteasomal degradation.
Methylated at Arg-1810 by CARM1. Methylation occurs only when the CTD is hypophosphorylated, and phosphorylation at Ser-1805 and Ser-1808 prevent methylation (in vitro). It is assumed that methylation occurs prior to phosphorylation and transcription initiation. CTD methylation may facilitate the expression of select RNAs.
Nucleus.
Target information above from: UniProt accessionP24928
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Western blot - RNA polymerase II antibody (ab52202)

All lanes : Anti-RNA polymerase II CTD repeat YSPTSPS antibody (ab52202) at 1/500 dilution
Lane 1 : COS7 cells treated
with EGF (200ng/ml, 30min), without immunising peptide
Lane 2 : COS7 cells treated
with EGF (200ng/ml, 30min), with immunising peptide
Predicted band size : 217 kDa
Observed band size : 217 kDa
Immunohistochemistry (Paraffin-embedded sections) - RNA polymerase II antibody (ab52202)

Immunohistochemical analysis of RNA polimerase II expression in paraffin embedded human breast carcinoma tissue using ab52202 at 1/500.
Left: sample without immunising peptide.
Right: sample with immunising peptide (negative control).
ab52202 has not yet been referenced specifically in any publications.
Publishing research using ab52202? Please let us know so that we can cite the reference in this datasheet
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:

All lanes : Anti-RNA polymerase II CTD repeat YSPTSPS antibody (ab52202) at 1/500 dilution
Lane 1 : COS7 cells treated
with EGF (200ng/ml, 30min), without immunising peptide
Lane 2 : COS7 cells treated
with EGF (200ng/ml, 30min), with immunising peptide
Predicted band size : 217 kDa
Observed band size : 217 kDa

Immunohistochemical analysis of RNA polimerase II expression in paraffin embedded human breast carcinoma tissue using ab52202 at 1/500.
Left: sample without immunising peptide.
Right: sample with immunising peptide (negative control).
0
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Call 01223 696 000 or contact us
